Officially Launching International Market Expansion

Leveraging Regenerative Medicine Technologies to Connect Global Markets and Advance Toward Becoming Asia's Leading Human Tissue Medicine Company

Issued by | ECM Biomedical – Marketing & Public Relations Department

Taipei, Taiwan

ECM Biomedical today announced the establishment of its U.S. subsidiary, officially launching the Company's international market expansion and marking a significant milestone in its journey from Taiwan to the global stage. The U.S. subsidiary will serve as a strategic hub for global operations and business development, strengthening connections across the international human tissue supply chain, clinical healthcare resources, and commercial distribution networks. This initiative will accelerate the global adoption of ECM Biomedical's regenerative medicine technologies and products while enhancing the Company's international competitiveness.

Since its establishment in 2022, ECM Biomedical has remained committed to advancing human tissue preservation, regenerative medicine technologies, and comprehensive quality management systems. The Company has successfully established an ISO Class 7 (Class 10,000) cleanroom manufacturing facility and obtained multiple TFDA Human Tissue Bank licenses, creating a diversified human tissue platform encompassing amniotic membrane, dermis, cortical bone, and bone graft products. These achievements have laid a solid foundation for the Company's sustainable growth and technological leadership.

In recent years, ECM Biomedical has strategically expanded three core product platforms: AmnioLink® for amniotic membrane matrix, DermaForm® for decellularized human dermis, and OsteonForm® for human bone graft products. These platforms support a broad range of clinical specialties, including orthopedics, sports medicine, rehabilitation medicine, plastic and reconstructive surgery, neurosurgery, dentistry, and aesthetic medicine, continuously expanding the clinical applications of regenerative medicine and human tissue technologies.

The establishment of the U.S. subsidiary represents not only a major milestone in ECM Biomedical's globalization strategy but also the foundation of its international operating platform. Through its U.S. presence, the Company will strengthen collaborations with global human tissue partners, healthcare institutions, and academic organizations while enhancing supply chain integration, regulatory strategy, market development, and commercial operations. These efforts will further reinforce the Company's global competitiveness and accelerate the expansion of its international market presence.

ECM Biomedical stated that the Company remains committed to its mission, "Advancing Healing with the Gift of Humanity," transforming the natural regenerative potential of human tissues into innovative medical solutions that provide healthcare professionals worldwide with high-quality regenerative medicine options. Looking ahead, the Company will continue investing in product innovation, quality management, clinical collaboration, and global regulatory strategies to strengthen its product portfolio, enhance brand recognition, and expand its presence across the Americas, Asia, and other international markets.

Guided by its core values of Human First, Science with Purpose, and Regulatory Integrity, ECM Biomedical will continue to deepen global partnerships and collaborate with international healthcare institutions and industry leaders to advance innovation in human tissue medicine and regenerative medicine. The Company is committed to becoming Asia's leading human tissue medicine company, bringing Taiwan's regenerative medicine expertise to the global healthcare community and creating lasting value for patients and medical professionals worldwide.